Document Detail

The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics.
MedLine Citation:
PMID:  12477218     Owner:  NLM     Status:  MEDLINE    
In a recent placebo-controlled study in mild atopic asthmatics, we observed a significant decrease in eosinophils in the bronchial submucosa, after 2 months oftreatment with inhaled formoterol and budesonide. Biopsy material from each treatment group; formoterol (24 microg bid), budesonide (400 microg b. i. d.) and placebo has been further assessed to investigatethe role of Th-2 cytokines by immunohistochemistry using Mabs to eosinophils as an index of inflammation, IL-4 and IL-5. Treatment with formoterol significantly reduced the number of eosinophils (EG2+) in the submucosa and epithelium, but this was not paralleled by changes in cytokine immunoreactivity In contrast, treatment with budesonide significantly reduced both the number of eosinophils (EG2+) and immunoreactivity for IL-4 and IL-5 in the submucosa. Thus, while budesonide has effects on cytokines involved in eosinophil recruitmentthis explanation does not apply tothe eosinopaenia observed with the long-acting beta2 adrenoreceptor agonist formoterol.
A Wallin; T Sandström; G D Cioppa; S Holgate; S Wilson
Related Documents :
6614638 - Airway responses to sulfate and sulfuric acid aerosols in asthmatics. an exposure-respo...
10194198 - Airway hyperresponsiveness to ultrasonically nebulized distilled water in subjects with...
17430338 - Patterns and dynamics of airway colonisation in mechanically-ventilated patients.
3823638 - Gas mixing in the human upper airways.
14555668 - High-speed running performance: a new approach to assessment and prediction.
24790488 - Evaluation of the physical activity biography: sport and transport.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Respiratory medicine     Volume:  96     ISSN:  0954-6111     ISO Abbreviation:  Respir Med     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2002-12-12     Completed Date:  2003-01-03     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  8908438     Medline TA:  Respir Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  1021-5     Citation Subset:  IM    
Department of Respiratory Medicine and Allergy, University Hospital, Umeå, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Administration, Topical
Adrenergic beta-Agonists / therapeutic use*
Anti-Inflammatory Agents / therapeutic use*
Asthma / drug therapy*,  immunology
Bronchi / immunology
Budesonide / therapeutic use*
Cytokines / analysis*
Double-Blind Method
Drug Therapy, Combination
Eosinophilia / drug therapy
Ethanolamines / therapeutic use*
Interleukin-4 / analysis
Interleukin-5 / analysis
Statistics, Nonparametric
Th2 Cells / immunology
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Anti-Inflammatory Agents; 0/Cytokines; 0/Ethanolamines; 0/Glucocorticoids; 0/Interleukin-5; 207137-56-2/Interleukin-4; 51333-22-3/Budesonide; 5ZZ84GCW8B/formoterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reduction of variability of exhaled nitric oxide in healthy volunteers.
Next Document:  Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler.